Prognostic biomarkers of chronic diabetic macular edema treated with a fluocinolone acetonide intravitreal implant [PDF]
, 2021 Background: This study aimed to investigate retinal imaging biomarkers, such as disorganization of the retinal inner layers (DRIL) and/or ellipsoid zone (EZ) disruption by spectral domain optical coherence tomography (SD-OCT), and functional outcomes in ...
Aerts , Florence +5 more
core +2 more sources
Ropivacaine vs tetracaine in topical anesthesia for intravitreal injection [PDF]
, 2015 Aim: The object of the study was to evaluate the long term efficacy and safety of ropivacaine 0,5% vs tetracaine 0,5% for topical anesthesia in intravitreal injection of dexamethasone in patients with diabetic macular edema (DME) and anti-vascular ...
COLLINI, Saul +6 more
core +1 more source
Anti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats. [PDF]
, 2016 Targeted drug delivery to the ocular tissues remains a challenge. Biodegradable intraocular implants allow prolonged controlled release of drugs directly into the eye. In this study, we evaluated an anterior suprachoroidal polyurethane implant containing
Ayres, E. +13 more
core +2 more sources
Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (Iluvien®) and follow-up considerations/ recommendations [PDF]
, 2020 Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting ...
Abraldes, M. +10 more
core +3 more sources
Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]
, 2019 The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto +5 more
core +1 more source
Predictors of Long-Term Visual Outcome in Intermediate Uveitis [PDF]
, 2017 PURPOSE: To describe factors that predict visual loss and complications in intermediate uveitis. DESIGN: Cross-sectional study. PARTICIPANTS: Subjects with intermediate uveitis were identified from a database of 1254 uveitis patients seen ...
Bar, A +4 more
core +1 more source
Current and Emerging Pharmacologic Therapies for Diabetic Retinopathy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 3, March 2026.ABSTRACT Diabetic retinopathy, a prevalent microvascular complication of diabetes mellitus, is a leading cause of blindness among adults in developed countries. Risk factors include prolonged duration of diabetes, elevated glycosylated hemoglobin levels, hypertension, and dyslipidemia, with rapid glucose reduction also increasing risk for developing ...
Jennifer N. Clements +2 more
wiley +1 more source
A low concentration of Tacrolimus/semifluorinated alkane (SFA) eyedrop suppresses intraocular inflammation in experimental models of uveitis [PDF]
, 2017 PURPOSE: Corticosteroids remain the mainstay therapy for uveitis, a major cause of blindness in the working age population. However, a substantial number of patients cannot benefit from the therapy due to steroids resistance or intolerance.
De Majumdar, S +5 more
core +3 more sources
Efficacy of Low-Release-Rate Fluocinolone Acetonide Intravitreal Implants to Treat Experimental Uveitis [PDF]
Archives of Ophthalmology, 2006 To determine the efficacy of 0.5-mg and 0.1-mg sustained-release fluocinolone acetonide intravitreal implants to inhibit ocular inflammation in a rabbit model of severe uveitis.The in vitro pharmacokinetic profile of both the 0.5-mg and 0.1-mg sustained-release fluocinolone intravitreal implants was determined during a 10-day period.
Prithvi, Mruthyunjaya +8 more
openaire +2 more sources
Implantable Drug Delivery Systems for Skeletal Muscles and Eyes
Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.This review highlights the different types of recent implantable drug delivery systems (IDDS) fabricated for a use with skeletal muscles, and with eyes. It presents the developments already made and the current research directions, showing the evolution of IDDS and their great diversity.
Serge Ostrovidov +8 more
wiley +1 more source